Ganzetti, Marco http://orcid.org/0000-0002-7049-171X
Graves, Jennifer S. http://orcid.org/0000-0003-1539-1940
Holm, Sven P. http://orcid.org/0000-0001-5947-3388
Dondelinger, Frank http://orcid.org/0000-0003-1816-6300
Midaglia, Luciana http://orcid.org/0000-0001-7981-2228
Gaetano, Laura http://orcid.org/0000-0002-5214-2858
Craveiro, Licinio http://orcid.org/0000-0002-8841-8035
Lipsmeier, Florian http://orcid.org/0000-0002-8663-819X
Bernasconi, Corrado http://orcid.org/0000-0002-1019-5468
Montalban, Xavier http://orcid.org/0000-0002-0098-9918
Hauser, Stephen L. http://orcid.org/0000-0002-4932-4001
Lindemann, Michael http://orcid.org/0000-0003-1010-3890
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 20 June 2022
Revised: 15 November 2022
Accepted: 17 November 2022
First Online: 5 December 2022
Change Date: 28 December 2022
Change Type: Update
Change Details: Figure 3 has been updated in the HTML as in the PDF
Declarations
:
: MG is a contractor for F. Hoffmann-La Roche Ltd. JSG over the past year has received grant/contract research support from the National MS Society, Biogen, and Octave Biosciences. She serves on a steering committee for a trial supported by Novartis. She has received honoraria for a non-promotional, educational activity for Sanofi Genzyme. She has received speaker fees from Alexion and BMS and served on an advisory board for Genentech. SPH is a contractor for F. Hoffmann-La Roche Ltd. FD was an employee of and is a shareholder in F. Hoffmann-La Roche Ltd; he is currently employed by Novartis Institutes for Biomedical Research. LM has nothing to disclose. LG is an employee of F. Hoffmann-La Roche Ltd. LC is an employee of and shareholder in F. Hoffmann-La Roche Ltd. FL is an employee of F. Hoffmann-La Roche Ltd. CB is a contractor for F. Hoffmann-La Roche Ltd. XM has received speaking honoraria and travel expenses for participation in scientific meetings; has been a steering committee member of clinical trials; or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, Genzyme, Immunic, Medday, Merck, Mylan, Nervgen, Novartis, Roche, Sanofi-Genzyme, Teva, TG Therapeutics, Excemed, MSIF, and NMSS. SLH serves on the scientific advisory boards for Alector, Annexon, and Accure; is on the Board of Directors for Neurona Therapeutics; and has received travel reimbursement and writing assistance from F. Hoffmann-La Roche Ltd and Novartis for CD20-related meetings and presentations. ML is a consultant for F. Hoffmann-La Roche Ltd via Inovigate.
: The study was registered on clinicaltrials.gov (NCT02952911). The study was conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. All participants provided informed consent and ethical approval was obtained from the ethics committee of the Vall d’Hebron University Hospital, Barcelona, Spain (study number: PR(AG)300/2016) and the institutional review board of the University of California San Francisco, San Francisco, CA, USA (reference number: 175728) prior to study initiation.